Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 14, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	886	415	234	106	395	405
Market Cap Growth	347.17%	77.46%	120.08%	-73.16%	-2.30%	-46.16%
Enterprise Value	934	484	301	121	363	241
Last Close Price	3.30	1.90	1.24	0.58	2.26	2.80
PS Ratio	3.76	2.59	1.20	0.36	1.87	1.37
PB Ratio	29.70	-8.43	-7.64	20.30	5.34	1.63
P/TBV Ratio	-	-	-	-	-	8.36
EV/Sales Ratio	4.58	3.02	1.55	0.41	1.71	0.82
EV/EBITDA Ratio	39.98	-	-	39.44	-	-
Debt / Equity Ratio	6.70	-3.84	-4.72	30.07	2.56	0.51
Debt / EBITDA Ratio	6.91	-	-	18.82	-	-
Asset Turnover	0.72	0.69	0.65	0.66	0.36	0.42
Inventory Turnover	1.69	1.64	2.13	0.77	1.67	0.72
Quick Ratio	1.77	1.07	0.82	1.01	0.79	1.59
Current Ratio	1.98	1.41	1.18	1.43	1.04	1.99
Return on Equity (ROE)	-	-	-	-237.83%	-175.37%	-119.82%
Return on Assets (ROA)	0.88%	-12.49%	-9.30%	-4.89%	-24.27%	-15.41%
Return on Capital (ROIC)	1.69%	-22.81%	-20.14%	-10.17%	-44.71%	-24.88%
Earnings Yield	-4.17%	-16.74%	-22.23%	-88.77%	-71.32%	-95.09%
FCF Yield	-0.29%	-9.82%	-10.01%	-69.03%	-63.99%	-27.35%
Buyback Yield / Dilution	-16.95%	-12.53%	-2.56%	-10.14%	-19.85%	-16.95%

Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q